tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alx Oncology Faces Nasdaq Delisting Risk Amid Stock Price Slump

Alx Oncology Faces Nasdaq Delisting Risk Amid Stock Price Slump

Alx Oncology Holdings, Inc. (ALXO) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Alx Oncology Holdings, Inc. faces a significant risk due to its potential delisting from the Nasdaq Global Select Market, which could adversely affect its stock liquidity and price. The company has been notified by Nasdaq of non-compliance with the minimum bid price requirement, as its stock has closed below $1.00 per share for over 30 consecutive business days. This situation threatens Alx Oncology’s ability to raise additional funds and maintain investor confidence. If the company fails to regain compliance within the given 180-day period, it may face further financial challenges and diminished market presence.

Overall, Wall Street has a Strong Buy consensus rating on ALXO stock based on 3 Buys and 1 Hold.

To learn more about Alx Oncology Holdings, Inc.’s risk factors, click here.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1